<DOC>
	<DOC>NCT02033096</DOC>
	<brief_summary>Follow-up, Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-202</brief_summary>
	<brief_title>Follow-up, Blinded-Outcomes Trial of Subjects Having Received IMP in Clinical Trial 64,185-202</brief_title>
	<detailed_description />
	<mesh_term>Jaundice</mesh_term>
	<mesh_term>Hyperbilirubinemia</mesh_term>
	<mesh_term>Hyperbilirubinemia, Neonatal</mesh_term>
	<mesh_term>Tin mesoporphyrin</mesh_term>
	<criteria>Subjects who have received IMP in clinical trial 64,185202 â€¢ Written informed consent provided by parents/guardians</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>stannsoporfin</keyword>
	<keyword>hyperbilirubinemia</keyword>
	<keyword>heme oxygenase</keyword>
</DOC>